Organisation paid for research Program year 2025 Source: CMS Open Payments

Barnet Dulaney Perkins Eye Center

Neither a doctor nor a teaching hospital

Research payments

$1,220,025

194 payments

Through program year 2025, Barnet Dulaney Perkins Eye Center is reported as receiving $1,220,025 in research payments, across 194 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $373,363 68
2024 Research $174,181 36
2023 Research $59,116 15
2022 Research $80,642 12
2021 Research $202,073 26
2020 Research $215,732 14
2019 Research $114,918 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $358,903 7 payments
  2. Genentech, Inc. $229,594 52 payments
  3. Alcon Research LLC $173,850 9 payments
  4. Regeneron Pharmaceuticals, Inc. $112,827 15 payments
  5. Kyowa Kirin, Inc. $109,768 38 payments
  6. Glaukos Corporation $81,721 49 payments
  7. Roche TCRC, Inc. $61,969 8 payments
  8. Hoffmann-La Roche Limited $34,586 2 payments
  9. Sight Sciences, Inc. $25,165 3 payments
  10. Allergan Inc. $14,846 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $288,539 4 payments
  2. Faricimab for Under Represented Patients With Dme $197,950 33 payments
  3. A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $97,191 7 payments
  4. A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema $84,408 30 payments
  5. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $70,365 3 payments
  6. Retrospective study looking at outcomes of Hydrus + OMNI canaloplasty stratified by ethnicity $49,063 1 payment
  7. Retrospective study looking at outcomes of Hydrus + OMNI canaloplasty stratified by ethnicity $49,062 1 payment
  8. Effectivity of DSLT as First Line Therapy for Primary Open Angle Glaucoma $46,593 1 payment
  9. A Study to Investigate Ro7200394 As Novel Intravitreal Treatment for Central Retinal Vein Occlusion $42,270 7 payments
  10. A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled $34,586 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record